ESCALATE
Interventional[Clinical Trial]
Study Design:
- Intervention Model Description: Lead-in open-label androgen-receptor blocker (ARB) followed by double-blind Radium-223 or placebo.
- Estimated Enrollment: 499 participants
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
Official Title:
ESCALATE, A Phase III Randomized Study Comparing Enzalutamide or Darolutamide With Radium-223 vs Enzalutamide or Darolutamide With Placebo and the Effect Upon Symptomatic Skeletal Event-Free Survival for mCRPC Patients